Wegovy 9 — Semaglutide 9 mg Tablets, 30 Tablets

Wegovy 9 mg is supplied in the form of oral tablets.

Qualitative and Quantitative Composition per Tablet:

• • Active Ingredient: Semaglutide — 9 mg.
• • Excipients: Salcaprozate sodium (SNAC), microcrystalline cellulose, magnesium stearate, tablet coating agents.

Packaging and Presentation: Round, biconvex tablets bearing "9" debossing. Each box contains 30 tablets. The outer carton reflects official Novo Nordisk branding featuring the corporate bull logo, generic name semaglutide, brand name wegovy, strength 9 mg, and administration details Oral use / 30 tablets.

Pharmacodynamics:
Semaglutide is a long-acting GLP-1 analogue with 94% human peptide homology. It binds to and activates GLP-1 receptors. Semaglutide increases insulin secretion and lowers glucagon secretion in a glucose-dependent manner. Weight loss mechanisms involve appetite reduction, decreased hunger, enhanced satiety, and delayed gastrointestinal motility.

Pharmacokinetics:

• • Absorption: Oral semaglutide absorption occurs primarily in the stomach. Peak plasma concentrations are reached 1 hour post-dose. The SNAC absorption enhancer facilitates gastric mucosal transport.
• • Distribution: High volume of distribution. Semaglutide is extensively bound to plasma proteins (>99%).
• • Metabolism: Metabolized via proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain.
• • Elimination: Eliminated primarily via renal and fecal excretion. The terminal half-life is approximately 1 week, supporting once-daily dosing to maintain steady-state concentrations.

Wegovy 9 mg is indicated in adult patients for:

• • Chronic Weight Management: As an adjunct to a reduced-calorie diet and increased physical activity for adult patients with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 to < 30 kg/m2) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
• • Cardiovascular Risk Reduction: To reduce major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity.

Wegovy 9 mg is taken orally once daily following strict protocols:

• • Timing and Conditions: Take in the morning on an empty stomach immediately upon waking. Swallow the tablet whole with no more than 120 ml of water.
• • Post-Dosing Restrictions: Do not eat, drink, or take any other oral medications for 30 minutes following administration, as this interferes with drug absorption.

Dose Escalation Schedule:
The 9 mg dose is administered during the third step of titration (month 3, days 61–90). Dose escalation proceeds every 30 days as follows: 1.5 mg (first 30 days) → 4 mg (month 2) → 9 mg (month 3) → 25 mg (target maintenance dose).

Administration of Wegovy 9 mg is contraindicated in:

• • Hypersensitivity: Known hypersensitivity to semaglutide or any inactive excipient.
• • Oncological History: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• • Pregnancy and Lactation: Contraindicated in pregnant or nursing women.
• • Severe Gastrointestinal Disease: Severe gastroparesis or acute inflammatory bowel disease flare-ups.
• • Pediatric Population: Safety and efficacy in individuals under 18 years of age have not been established.

Potential drug interactions should be evaluated during oral semaglutide therapy:

• • Absorption Impacts: Oral semaglutide may affect the pharmacokinetics of concomitant oral drugs due to delayed gastric emptying. Strict adherence to the 30-minute fasting window minimizes risks.
• • Narrow Therapeutic Index Drugs: Caution is advised when co-administering drugs requiring careful concentration monitoring (e.g., levothyroxine, warfarin).
• • Insulin and Secretagogues: Co-administration with insulin or sulfonylureas increases the risk of hypoglycemia.

Pregnancy:
Wegovy 9 mg is strictly contraindicated during pregnancy. Semaglutide poses potential fetal risks. Pregnancy planning requires discontinuing treatment at least 2 months prior to planned conception due to prolonged drug washout periods.

Lactation:
Data regarding human breast milk excretion are unavailable. The drug is contraindicated during breastfeeding.

The most frequent adverse events associated with GLP-1 receptor agonists involve the gastrointestinal tract, most pronounced during dose escalation phases:

• • Gastrointestinal Tract (Very Common): Nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, gastritis, flatulence, eructation, gastroesophageal reflux.
• • Metabolic Disorders: Decreased appetite, hypoglycemia (in diabetic patients).
• • Nervous System: Dizziness, fatigue, headache.
• • Cardiovascular System: Resting heart rate increases (sinus tachycardia).
• • Other: Pancreatic enzyme elevations (lipase and amylase), cholelithiasis.

Symptoms:
Overdose may result in pronounced adverse reactions, primarily gastrointestinal (severe nausea, vomiting, acute abdominal pain), along with a risk of symptomatic hypoglycemia.

Treatment:
No specific antidote exists. Supportive and symptomatic care should be administered, monitoring blood glucose and fluid-electrolyte balance. Hemodialysis is ineffective due to high plasma protein binding.

Storage Requirements for Wegovy 9 mg:

• 🌡️ Temperature Range: Store in a dry place protected from light at temperatures not exceeding 25–30 °C (77–86 °F). Do not freeze.
• ☀️ Moisture Protection: Keep in original closed packaging to protect tablets from moisture.
• 👶 Safety Precautions: Keep out of reach of children.
• ⏳ Shelf Life: Stated on the outer carton. Do not use past expiration date. Prescription-only medicine.

To verify the authenticity of original Wegovy 9 mg manufactured by Novo Nordisk, check the following visual and security features:

• ✅ Novo Nordisk Corporate Logo: Recognizable horned bull corporate logo located in the bottom right carton corner.
• ✅ Product Branding: Brand name "wegovy" printed in lowercase letters with a trademark symbol, accompanied by strength "9 mg" set inside a turquoise rectangular block.
• ✅ Carton Design: Clean white background complemented by smooth turquoise graphic wave accents and text reading Oral use / 30 tablets.
• ✅ Tablet Depiction: Graphic illustration of a round grey tablet featuring "9" debossing printed on the front box face.
• ✅ Security Features: Presence of 2D DataMatrix barcodes, serial numbers, and tamper-evident carton seals.